LASIK safe to correct myopia after retinal detachment
February 1st 2004Anaheim, CA-LASIK can be safe and effective for correcting refractive errors in eyes with previous retinal detachment surgery, although alternative procedures may need to be considered because obtaining adequate microkeratome suction to create the lamellar cut may sometimes be a challenge, said Irina S. Barequet, MD, at the International Society of Refractive Surgery/American Academy of Ophthalmology subspecialty day meeting.
Additive intralamellar surgery yields excellent results for keratoconus
February 1st 2004Anaheim, CA-Additive intralamellar corneal refractive surgery is an exciting new area of surgical development that may provide an alternative to penetrating keratoplasty for the optical rehabilitation of the keratoconus patient, said David J. Schanzlin, MD, who delivered the Barraquer Lecture at the annual meeting of the American Academy of Ophthalmology.
Greater understanding of ocular toxoplasmosis
February 1st 2004Anaheim, CA-Research-ers worldwide are focusing efforts on ocular toxoplasmosis in hopes of finding better preventive and treatment strategies for this parasitic disease, which can lead to permanent vision loss, according to Gary N. Holland, MD, who delivered the Jackson Memorial Lecture during the opening session of the American Academy of Ophthalmology annual meeting.
Baseline risk factors lower glaucoma surgery success rates
January 15th 2004Washington, DC-Ten-year data from the Advanced Glaucoma Intervention Study (AGIS) show that 60% to 70% of patients initially treated with argon laser trabeculoplasty or trabeculectomy fared well with these treatments. In the 30% to 40% of remaining patients, however, treatment failed to maintain visual field and visual acuity. Baseline risk factors for loss of visual field included worse visual acuity, male gender, and the presence of diabetes mellitus.
Generic brimonidine availability yields lower cost to patient
January 15th 2004Generic brimonidine tartrate (Bausch & Lomb), which is formulated differently from the trade formulation (Alphagan P, Allergan), became widely available during the second half of 2003 and seems to be gaining acceptance with ophthalmologists in many cases because of the drug's lower cost.
Allergic response to brimonidine may remain in other forms
January 15th 2004Albany, CA-Patients with glaucoma who have had an allergic ocular reaction to brimonidine 0.2% (Alphagan, Allergan) also experience an allergic ocular reaction to brimonidine Purite 0.15% (Alphagan P). In patients with a known allergic response to brimonidine, the likelihood of the same reaction to the reformulation is high.
Fixed-combination drug beneficial in glaucoma therapy
January 15th 2004The fixed combination of timolol-dorzolamide (Cosopt, Merck) can be beneficial in glaucoma therapy for several reasons: prescribed in conjunction with a single agent such as a prostaglandin analog, it may achieve a greater reduction in the patient's IOP than the single agent alone, and it can improve compliance, according to two glaucoma experts.
Ruboxistaurin reduces visual loss in diabetic retinopathy
January 15th 2004New Orleans-Ruboxistaurin mesylate, a protein kinase C (PKC) beta inhibitor, reduces loss of vision in patients with moderate-ly severe to very severe nonproliferativediabetic retinopathy, researchers reported at the American Diabetes Association meet-ing here.
Factors profile riskfor malpractice claims
January 15th 2004Anaheim, CA-Results of a retrospective, longitudinal cohort study point to specific physician-related factors that significantly increase the risk of LASIK/PRK malpractice liability claims and lawsuits, said Richard L. Abbott, MD, at the International Society of Refractive Surgery/American Academy of Ophthalmology subspecialty day meeting.
Wavefront research still aiming toward perfect vision
January 15th 2004Anaheim, CA-The quest to achieve perfect vision with wavefront-guided laser surgery began just a few years ago and is still continuing on a path to discovery, said Michael C. Mrochen, PhD, at the International Society of Refractive Surgery/American Academy of Ophthalmology sub- specialty day meeting.
Choice of medication should be determined case by case
January 15th 2004Philadelphia-In about 80% of glaucoma cases, medication is the preferred initial approach for lowering IOP. However, the choice of medication must be made with the cognition of individual patient differences that can affect the tolerability and effectiveness of the drug, noted Marlene Moster, MD, clinical professor of ophthalmology, Thomas Jefferson Medical Col- lege, Philadelphia.
Not all hypotensive lipids act the same for individuals
January 15th 2004The advantages of the hypotensive lipids bimatoprost (Lumigan, Allergan), latanoprost (Xalatan, Pfizer), and travoprost (Travatan, Alcon) over timolol 0.5% (Timoptic, Merck) have been conclusively demonstrated in phase III clinical trials. As a class, these therapies have been shown to reduce IOP and to reduce fluctuations of the diurnal curve significantly. Yet, it is important to understand that despite these commonalities, differences also exist. It is only in understanding these differences, and matching them clinically to the individual profile of the patient, that we can choose the right drug at the right time.
Prostaglandin analogs help patients stick with regimen
January 15th 2004Baltimore-Patients prescribed latanoprost (Xalatan, Pfizer Ophthalmics) continue therapy significantly longer than their counterparts using other prostaglandin-type drugs, according to the results of a population-based, retrospective cohort study.
Autoantibody repertoires could be key in glaucoma research
January 15th 2004Mainz, Germany-Analysis of autoantibody repertoires using advanced pattern-matching algorithms, such as artificial neural networks, may be useful for diagnosis of glaucoma, said Franz H. Grus, MD, PhD. He is the group leader of the experimental ophthalmology unit ("Pathophysiology of the Eye"), department of ophthalmology, University of Mainz, Germany.
Soft punctal plugs ease dry eye after laser-vision correction
January 15th 2004Charleston, WV-Findings of a bilateral comparison study evaluating prophylactic punctal occlusion in patients undergoing laser- vision correction surgery indicate soft plugs (Soft Plug-SA, Oasis Medical) may provide greater comfort and for a longer duration than standard collagen plugs.
ACES, SEE meeting offers networking opportunities
January 15th 2004Between sessions, many networking opportunities are available to attendees. Delegates might enjoy one of two 2-hour bike tours of the island, visiting an archeological site, the Old Burnham Clam Factory, and the five-story mansion and former home of Bob Turley, the New York Yankees pitcher who threw the first 100-mph fastball.
Cole Eye Institute wins grant for imaging study
January 15th 2004Cleveland-The National Eye Institute has awarded Cleveland Clinic's Cole Eye Institute a $6 million grant to study advanced imaging for glaucoma (AIG). The Cole Eye Institute is organizing and coordinating a multicenter effort to develop and test advanced imaging technologies for the diagnosis and management of glaucoma.
Suction rings, software update allow for greater microkeratome control
January 1st 2004Advanced Medical Optics (AMO) has introduced three new suction rings and updated the software used in conjunction with the rings for its Amadeus microkeratome, features that increase the safety and versatility of the device, said physicians who are familiar with the upgraded product.
Various factors affect thickness of LASIK flaps
January 1st 2004Camarillo, CA-Analysis of the variables that can affect flap thickness in LASIK showed that thickness increased with greater microkeratome head plate depth, higher preoperative central corneal thickness, and smaller microkeratome suction ring diameter.
FDA approves first accommodative IOL
January 1st 2004Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Femtosecond laser minimizes wavefront distortions
January 1st 2004Irvine, CA-Standard refraction and vision outcome measures were found to be excellent and comparable in eyes undergoing LASIK flap creation with the femtosecond laser (IntraLase FS, IntraLase Corp.) versus with a mechanical microkeratome, but flap construction with the femtosecond laser is associated with less change in ocular aberrations, according to Dan B. Tran, MD.
Zero compression head dramatically cuts risk of epithelial defect
January 1st 2004St. Louis-Epithelial defect risk associated with the Hansatome microkeratome (Bausch & Lomb) is significantly reduced by use of the zero compression head, according to the results of a retrospective study undertaken by Stephen A. Wexler, MD.
Microkeratome creates flaps for LASIK, LASEK procedures
January 1st 2004Barranquilla, Colombia-The Carriazo-Pendular microkeratome (Schwind Eye-Tech Solutions) is a highly versatile microkeratome that can be used with great safety to produce high-quality flaps for LASIK and perhaps even for LASEK procedures, said Cesar Carriazo, MD.